Table 3.

Synthesis matrix of articles collected in a literature review that report the antibacterial potential of synthetic Chalcones and derivatives against S. aureus

Chalcone	Type	Synthesis technique	S. aureus strain (s)	MIC/Inhibition Zone	Activity	Quote
(E)-1-(2-hydroxyphenyl)-3-(2,4-dimethoxy-3-methylphenyl)prop-2-en-1-one	Synthetic	–	1199B	↓ 50% of the MIC of the antibiotic (128 μg/mL to 64 μg/mL);	Antibacterial; Synergism with the antibiotic Norfloxacin Inactive as a NorA inhibitor	Rocha et al. (2021)
(E)-1-(2-hydroxyphenyl)-3-(2,4-dimethoxy-3-methylphenyl)prop-2-en-1-one	Synthetic	–	K2068	↓ 60.3% of the MIC of BrEt (32 μg/mL to 12.6992 μg/mL)	Inactive for direct antibacterial activity. Synergism with BrEt and potential MepA efflux pump inhibitor	Rocha et al. (2021)
(Z)-4-((bis(2-hydroxyethyl)amino)methyl)-7-((1-(4-methoxyphenyl)-3-oxo-3-(thiazol-2-yl) prop-1-en-2-yl) oxy)-2H-chromen-2-one (5i)	Synthetic	–	MRSA	0.004 mM	Antibacterial 6X better than the reference antibiotic Norfloxacin	Hu et al. (2021)
4-bromo-3'-aminochalcone (5f)	Synthetic	Claisen–Schmidt	MSSA MRSA	1.9 μg mL; 7.8 µg mL	Concentration-dependent antibacterial and antibiofilm	Garcia et al. (2021)
Chalcones derived from 2-hydroxyacetophenone (A1-A6)	Synthetic	Claisen–Schmidt	RN4220; K4414; 1199B; K2068	1024 μg/mL	Clinically irrelevant antibacterial activity; Potential IBEs	Xavier et al. (2021)
Chalcone derivative DBDCPP-3	Synthetic	Claisen–Schmidt	–	Over than 15 mm	Bactericide	Shinde et al. (2021)
(E)-3-(furan-2-yl)-1-(2-hydroxy-3,4,6-trimethoxyphenyl)prop 2-en-1-one (Hitfurfural); (E)-1-(2-hydroxy-3,4-dimethoxyphenyl)-3-(thiophen-2-yl)prop-2-en-1-one (Hithiophene)	Synthetic	Claisen–Schmidt	1199B K2068	1024 μg/mL	Clinically irrelevant antibacterial activity; Potential NorA and MepA IBEs	da Silva et al. (2021)
(2E)-3-(4-Methoxyphenyl)-1-{4-[(3-phenyl-1,2,4-oxadiazol-5- yl)methoxy]phenyl}prop-2-en-1-one (6a)	Synthetic	–	–	3.12 μM 2 × more efficient than the standard drug Ciprofloxacin	Antibacterial	Ibrahim et al. (2021)
(E)-3-(3-bromo-4-methoxyphenyl)-1-(thiazol-2-yl)prop-2-en-1-one (Zn 4 complex)	Synthetic	Claisen–Schmidt	MTCC 916	18 mm	Antibacterial	Johnson and Yardily (2021)
(E)-3-(4-(dimethylamino)phenyl)-1-(2-hydroxyphenyl)prop-2-en1-one (3)	Synthetic	Claisen–Schmidt	1199B	1000 μg/mL	Clinically irrelevant antibacterial activity; NorA inhibitory potential	Leal et al. (2021)
Polymer chalcone (P3)	Synthetic	Claisen–Schmidt	–	20 mm	Antibacterial	Solmaz et al. (2021)
Hybrid Chalcona (1)	Synthetic	Claisen–Schmidt	NCIM 2122	10.05 μM	Low antibacterial activity compared to standard drug Ciprofloxacin	Konidala et al. (2021)
Chalcone with imide-Zo portion [1,2-a]pyridine (3b, 3d, 3g, 3l and 3m)	Synthetic	Claisen–Schmidt	–	32 μg/mL and 64 μg/mL	Antibacterial	Soltani et al. (2021)
E4,4'-Bromo-4-methylchalcone	Synthetic	Claisen–Schmidt	MRSA	16 μg/mL	Antibacterial	Aksöz et al. (2021)
Quinoline chalcone: 1-(4-(benzyl sulfonyl) phenyl)- 2,3dibromo-3-(chloroquinoline-3-yl) propane-1- one (7)	Synthetic	Claisen–Schmidt	–	At a concentration of 10 mg/disk: 15 mm	Low antibacterial activity compared to standard drug	Saleh et al. (2020)
Fluorinated chalcone: (E)-3-(1″H-indol-3″-yl)-1-[40 -(trifluoromethyl)phenyl]prop-2-en-1-one	Synthetic	Claisen–Schmidt	NCIM-2079	51 µM	Low antibacterial activity compared to standard drug	Lagu et al. (2020)
(E)-1-(4-aminophenyl)-3-(furan-2-yl)-prop-2-en-1-one (AFPO)	Synthetic	Claisen–Schmidt	10	≥ 1024 μg/mL	Irrelevant	Ferraz et al. (2020)
(E)-1-(4-aminophenyl)-3-(furan-2-yl)-prop-2-en-1-one (AFPO)	Synthetic	Claisen–Schmidt	10	AFPO + Gentamicin: ↓ 3X AFPO + Penicillin = ↓ 3X	Synergism (potentiation of antibiotic activity)	Ferraz et al. (2020)
Naphthyl Chalcones (3a -3p)	Synthetic	–	MTCC 96	24–162 μg/mL	Low antibacterial activity compared to standard drug	Pola et al. (2020)
Heteroaromatic Chalcones Derivatives (1a-and 3a-c)	Synthetic	Claisen–Schmidt	N5923	13 and 19 mm	Antibacterial	Farooq and Ngaini (2020)
Chalcone derivative (1d)	Synthetic	Claisen–Schmidt	–	11 mm	Antibacterial	Farooq and Ngaini (2020)
Chalcones source of the natural product 2-hydroxy-3,4,6-trimethoxyacetophenone (1–4)	Synthetic	Claisen–Schmidt	10 (Multi-resistant); ATCC 25923;	≥ 1024 μg/mL; 645 μg/mL	Irrelevant; Low antibacterial activity and synergism with Ciprofloxacin and Gentamicin	Freitas et al. (2020)
4'-piperazinyl Chalcone—pleuromutilin (14i; 14k)	Synthetic	Alcoholic condensation	MRSA (ATCC 33591); MRSA (ATCC 43300); ATCC 25923	0.5–1 μg/mL	Antibacterial	Xie et al. (2020)
Sulfonamides Chalcones and derivatives: (IV—XXXII)	Synthetic	–	ATCC 25923	(> 22)—10 (0.156) mm	Inactive for antibacterial activity	Bonakdar et al. (2020)
Ferrocenyl Chalcones (Decyl)	Synthetic	Acquired	NCIMB 8244 MRSA (RCH)	0.031 mg mL 0.063 mg mL	Antibacterial	Henry et al. (2020)
Bichalcones and Bispirazoline derivatives (2ª–2d) (3b–3d)	Synthetic	Acquired	–	16–32 μg/mL 8 – 32 μg/mL	Inactive for antibacterial activity	Nisa and Yusuf (2020)
Pyrimidine derived from Chalcone: 9-(Benzo[d][1,3]dioxol-5-yl)- 7-(thiophen-2-yl)pyrido[30,20:4,5] thieno[3,2-d]pyrimidin-4(3H)-one (24a)	Synthetic	Acquired	ATCC 6538	7.81 μg/mL	Antibacterial	Sanad et al. (2020)
Triazine Chalcone: 3k	Synthetic	Claisen–Schmidt	NCIM 2178	85 mm	Antibacterial	Shinde et al. (2019)
Aminochalcone derivatives: 1–3; 7–8; 11–13; 16	Synthetic	Claisen–Schmidt	DSM799	0.25 [mg/mL]; 0.125 [mg/mL]; 0.25 [mg/mL]; 0.5 [mg/mL]	Antibacterial	Kozłowska et al. (2019)
Chalcones and derivatives (6r, 12a); [6s; 12c] 7j–7m	Synthetic	Claisen–Schmidt	MSSA (ATCC 29213); MRSA (USA 300)	(1.56 − 6.25 μg/mL); [3.125 − 6.25 μg/mL]; 1.56 -12.5 μg/mL	Antibacterial	Zhang et al. (2018b)
Chalcones bonded to Biscoumarine copolyester 4a; 4b; 4c	Synthetic	Polycondensation	–	312.5 μg/mL; 625 μg/mL; 156.2 μg/mL	Antibacterial	Kandaswamy (2019)
1-(2-bromophenyl) ethanone derivatives I1-I5	Synthetic	–	NCIM 2079	They ranged from 31.25 to 500 μg/mL	Significant Antibacterial	Prasad et al. (2018)
Chalcones derivatives 11; 18	Synthetic	Claisen–Schmidt	NTCC8325-4 MRSA 97-7	50 and 70 µg/mL; 50 and 90 µg/mL	Low antibacterial activity	Vásquez-Martínez et al. (2019)
Chalcones derivatives 18; 11	Synthetic	Claisen–Schmidt	MRSA 97-7	20 μg/mL; 50 μg/mL	Synergism with the antibiotic methicillin	Vásquez-Martínez et al. (2019)
Chalcone-pyridine hybrids 5j; 5i; 5b; 5f	Synthetic	–	MTCC 121	3.12 μg/mL; 6.25 μg/mL	Antibacterial	Gondru et al. (2018)
Pyrimidine-2(1H)-ol/-thiol derivatives derived from Chalcones 20–24; 35–39	Synthetic	–	ATCC 25923	2.1–138.8 µg/mL	Antibacterial	Fandakli et al. (2018)
Chalcones converted to pyrazoles 4h, 4j, 4l, 4m e 4n	Synthetic	Claisen–Schmidt	–	They ranged from 3.75 to 1.25 µg/mL	Antibacterial	Chowdary et al. (2019)
Benzoxazepines derived from pyrazol-Chalcones 3c; 3h, 5c, 5g; 5b; 5h	Synthetic	–	–	30 mm; 28 mm; 27 mm; 32 mm	Antibacterial	Ashok et al. (2018)
Indolyl Chalcone Derivatives 4b; 5b; 6b, 7; 11	Synthetic	–	–	27 mm; 22 mm; 24 mm, 28 mm	Antibacterial	Sayed et al. (2018)
Heterocyclic Chalcones 4b* 4c, 4g, 4k	Synthetic	Claisen–Schmidt	MTCC 096	12.5 µg/mL* 6.25 µg/mL	Antibacterial	Kaushik et al. (2018)
Pyrazole Chalcones 6b; 6c; 7b e 8b	Synthetic	Claisen–Schmidt	MTCC9886	13 ± 0.44 mm; 17 ± 1.10 mm; 15 ± 0.53 mm; 11 ± 2.01 mm	Moderate antibacterial	Kumari et al. (2018)
Triazole-based Chalcones and its derivatives 3f, 5a, 6a, 7b e 8a	Synthetic	–	–	44.59 mM; 50.15 mM; 66.61 mM; 76.63 mM; 53.86 mM	Antibacterial	Santosh et al. (2018)
Anthracene-based Chalcone derivatives ANNP, ANFL; ANID and ANPT	Synthetic	Claisen–Schmidt	–	6.25 µg mL; 3.12 µg mL	Moderate antibacterial	Prakash et al. (2018)
Chalcones derived from acetylpyridines 4; 5; 11; 12	Synthetic	–	–	–	Antibacterial	Santra et al. (2018)
β-Carboline Chalcones and their bromide salts 12b, 12c, 12e, 12f, 12g; 13a; 13h	Synthetic	–	MTCC 96	Ranged from 440 to > 900 µM	Inactive for antibacterial activity	Reddy et al. (2018)
Chalcone-thiazole hybrids (27)	Synthetic	Claisen–Schmidt	ATCC 33592—Methicillin and Gentamicin Resistant	1.4 µM	Antibacterial	Sashidhara et al. (2015)
1,3- diphenyl-2-propen-1-ones (III-C)	Synthetic	–	JMC 2151	32 ± 1.5 mm	Antibacterial	Alam et al. (2015)
Chalcones derivatives: 3ª–3j	Synthetic	–	ATCC 29213; (MRSA)	16–256 μg/mL 32–64 μg/mL	Low antibacterial activity	Evranos-Aksöz et al. (2015)
4.5-dihydropyrazol	Synthetic	–	ATCC 29213	10–17 mm	Antibacterial	Budak et al. (2017)
2-(4-Methyl-2-oxo-2H-chromen-7-yloxy)-N-(4-((E)-3- (3,4,5-trimethoxyphenyl)acryloyl)phenyl)acetamide	Synthetic	Claisen–Schmidt	ATTC 6538	35.8 µg/mL	Antibacterial	El-Sherief et al. (2017)
(4- (4- aryl)-1H- pyrrol-3-yl)(pyren-1-yl)meth- Anone + (3-chloro)	Synthetic	-	-	4.1 μg/mL	Antibacterial	Divakar and Shanmugam (2017)
monocarbonyl curcuminoids	Synthetic	-	ATCC 25923	250 mg/mL	Antibacterial	Ud Din et al. (2017)
2-(2-Hydroxyphenyl)-5-methyl-3-(4-(thiophen-2-yl)-6-(4- methyl-phenyl)-pyrimidin-2-yl) thiazolidin-4-one; 3-Chloro-4-(4-hydroxy-3-methoxyphenyl)-1-(4-(thiophen-2- yl)-6-(4-methyl-phenyl)-pyrimidin-2-yl)azetidin-2-one	Synthetic	Claisen–Schmidt	–	100 μg mL	Antibacterial	Patel et al. (2017)
(2E,20 E)-3,30 -(3,30 -(butane-1,4-diylbis(oxy))bis(3,1- phenylene))bis(1-(thiophen-2-yl)prop-2-en-1-one) (2E,20 E)-3,30 -(3,30 -(pentane-1,5-diylbis(oxy))bis(3,1- phenylene))bis(1-(thiophen-2-yl)prop-2-en-1-one)	Synthetic	Claisen–Schmidt	MTCC 96	8 μg/mL	Antibacterial	Yusuf et al. (2017)
Chalcones derived from Pyrimidines	Synthetic	–	–	9–14 mm	Antibacterial	Kumar et al. (2017b)
Phenylpropenone pyrrolyl Chalcone	Synthetic	–	–	6–11 mm	Antibacterial	Kumar et al. (2017a)
Chalcones with a triazine nucleus (P1–P3, P5, P6, S6)	Synthetic	–	MTCC 96	7–13 mm	Antibacterial	Mahmoodi et al. (2017)
Derivatives of (3ar,4S,7R,7as)-2-(4-((E)-3-(3- aryl)acryloyl) phenyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole1,3(2H)-dione (7e, 7l, 7m and 7n)	Synthetic	Claisen–Schmidt	ATCC 29213	14 mm	Antibacterial	Kocyigit et al. (2017)
(2E)-3-(2,6- dichlorophenyl)-1-(4-methoxyphenyl) prop-2-en-1-one	Synthetic	–	–	50 mg/mL	Antibacterial	Sadgir et al. (2020)
Chalcones derived from Pyrazoline	Synthetic	–	–	12.5–25 µg/ml	Antibacterial	Desai and Sastry (2017)
6,6-dimethyl3-aryl-3′,4′,6,7-tetrahydro-1′H,3H-spiro[benzofuran-2,2′-naphthalene]-1′,4(5H)- dione (5a)	Synthetic	Claisen–Schmidt	ATCC 29213	16 mm	Antibacterial	Ergüntürk et al. (2017)
2-Pyrazoline (5f)	Synthetic	Claisen–Schmidt	MTCC 737	10 mg/mL	Antibacterial	Lokeshwari et al. (2017)
2-bromo-4-[3-(2-hydroxyphenyl)-4,5-dihydro-1h-pyrazol-5-yl]-6-methoxyphenol 1-[5-(3-bromo-4-hydroxy-5-methoxyphenyl)-3-(2-hydrophenyl]-4,5-dihydro-1H-pyrazol-1-yl)ethanone	Synthetic	–	FNCC 0047	7.25 mm	Antibacterial	Setyawati et al. (2017)
Cis-3-4-dihydrohamacanthin B; Bromodeoxytopsentin	Synthetic	–	RN4220; MRSA 252; ATCC 29213	12.5 µg/mL; 6.25 µg/mL	Antibacterial	Labrière et al. (2017)
(2E,2′E)-3,3′-(octane-1,8-diylbis(oxy))bis(3,1- phenylene))bis(1-phenylprop-2-ene-1-one) 1,12-bis(3-(1,3-diphenyl-4,5-dihydro-1H-pyrazol5-yl)phenoxy)dodecane	Synthetic	Claisen–Schmidt	MTCC 96	8 μg/mL	Antibacterial	Yusuf et al. (2017)
Jaceosidin; 5,7,4′-triacetoxy jaceosidin	Synthetic	–	ATCC 43,300, VRS 10, NRS 17 NRS 1	32–128 µg/mL	Antibacterial	Kumar et al. (2016)
3′-formyl-2′,4′,6′-trihydroxydihydrochalcone	Synthetic	–	ATCC 29,213 MRSA 33,591	17.4 μM 36.6 μM	Antibacterial	Zaki et al. (2016)
Quinoline scaffold (3b, 3d, 3g, 3h–j)	Synthetic	Claisen–Schmidt	-	200 µg/mL	Antibacterial	Dave and Rahatgaonkar (2016)
Ferrocenyl chalcones with O-alkylated vanillins	Synthetic	Claisen–Schmidt	ATCC 25923	0.625–5 µg/mL	Antibacterial	Muškinja et al. (2016)
Complex Chalcones (3e, 3l)	Synthetic	–	ATCC 43300	21.8% Redução de crescimento	Antibacterial	Patil et al. (2016)
(E)-3-{5-[(2-Benzoylbenzofuran-5-yl)methyl]-2- hydroxyphenyl}-1-(3,4-dichlorophenyl)prop-2-en-1- one; {5-[3-(8-Fluoro-4-phenyl-2,3-dihydro-1H-benzo- [b][1,4]diazepin-2-yl)-4-hydroxybenzyl]benzofuran2-yl}(phenyl)methanone	Synthetic	Claisen–Schmidt	–	55 µg/mL 34 µg/mL	Antibacterial	SHankar et al. (2016)
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-chlorophenyl)methanone (4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone (4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone	Synthetic	–	ATCC 6538	200–400 µg/mL	No significant antibacterial activity	Patel et al. (2016)
Carbazole-based Chalcones (3a, 3h, 3i, 4a, 4h, 4i, 5a, 5h, 5i)	Synthetic	Claisen–Schmidt	ATCC 6538	20 µg/mL	Antibacterial	Ashok et al. (2016)
Glabridin-chalcone hybrid molecules (6h, 7e, 8f)	Synthetic	Claisen–Schmidt	MTCC-96 MRSA-ST 2071	12,5 µg/mL	Antibacterial	Kapkoti et al. (2016)
Chalcones derived from 1,3-diaryl pyrazole (6g, 6l and 7l)	Synthetic	–	4220	1–64 μg/mL	Antibacterial	Killeen et al. (2016)
Chalcones Derivatives (4ª, 4f)	Synthetic	Claisen–Schmidt	4220, 209 and 503	2 μg/mL	Antibacterial	Wei et al. (2016)
1-[7-(diethylamino)-2H-chromen-2on]-3-(p-chlorophenyl)-2-propen-1-one one; 1-[7-(diethylamino)-2H-chromen-2on]-3-(p-fluorophenyl)-2-propen-1-one	Synthetic	Claisen–Schmidt	–	100 µg/mL	Antibacterial	Himangini and Pathak (2016)
4,5-Dihydro-3-(1-benzyl-1H-indol-3-yl)-5-(naphthalene-2-yl) isoxazole	Synthetic	Claisen–Schmidt	RCMB 010028	23.4 mm	Antibacterial	Abo-Salem et al. (2016)
1,3-thiazine compounds with a Schiff base portion (5a-5e)	Synthetic	Claisen–Schmidt	–	09–15 mm	Antibacterial	Babu et al. (2015)
2,8- bis(2,4-Dichlorophenyl)-4H,6H-pyrano[3,2-g]chromene-4,6-dione	Synthetic	Claisen–Schmidt	ATCC 29737	12.5 µg/mL	Antibacterial	Husain et al. (2015)
2-Chloro-N-{4-[3-(substitutedphenyl)-acryloyl]-phenyl}-acetamide	Synthetic	Claisen–Schmidt	–	9 mm	Antibacterial	Jayaramu and Maralihallia (2015)
3-(4′-N,N-dimethyl amino phenyl)-5-(2″, 2″-dimethyl, 7″-hydroxy chroman) isoxazole/3-(3′,4′-chloro-phenyl)-5-(2″, 2″-dimethyl, 7″-hydroxy chroman) isoxazole/3-(4′-methoxy-phenyl)-5-(2″, 2″-dimethyl, 7″-hydroxy chroman) isoxazole/3-(4′-cyano phenyl)-5-(2″, 2″-dimethyl, 7″-hydroxy chroman) isoxazole	Synthetic	Claisen–Schmidt	MTCC 96	5–20 µg/mL	Antibacterial	Raju et al. (2015)
trans-3-(1H-indol-3-yl)-1-(40-benzyloxyphenyl)-2-propen-1-one (2), 1-(400-biphenyl)-3-(30 40-dihydroxyphenyl)-2-propen-1-one (11), 1-(400-hydroxy-300-methylphenyl)-3-(40 -hydroxyphenyl)-2-propen-1-one (14), 3-(40 -chlorophenyl)-1-(400-hydroxyphenyl)-2-propen-1-one (17), LTG-oxime	Synthetic	Claisen–Schmidt	ATCC 96 MRSA	12.5–50 mg mL	Antibacterial	Gaur et al. (2015)
6H-benzo[c]chromen-6-ones and Diazepines (10a,b)	Synthetic	Claisen–Schmidt	ATCC 9144	0.625 μg/mL	Antibacterial	Mazimba (2015)
Chalcone	Synthetic acquired	–	USA 300; USA 300 ΔSRTA	53.15 μM 76 μM	Antibacterial and anti-biofilm	Zhang et al. (2017)
Apchal and Achlopheny	Synthetic	Claisen–Schmidt	ATCC 25923, 10, 1199B, K2068	70% synergism of gentamicin when associated with Apchal and loss of synergism when associated with Aclo-phenyl	Antibacterial. Synergism and antagonism were observed	Siqueira et al. (2020)
Apchal and Achlophenyl	Synthetic	Claisen–Schmidt	SA-1199B; K2068	Synergism with Norfloxacin and ciprofloxacin; synergism with ciprofloxacin and ethidium bromide	Efflux pump inhibitor	Siqueira et al. (2020)
1,3- Bis-(2-hydroxy-phenyl)-propenone, 3-(3-hydroxy-phenyl)-1-(2-hydroxy-phenyl)-propenone e 3-(4-hydroxy-phenyl)-1-(2-hydroxy-phenyl)-propenone	Synthetic	–	MRSA ATCC 43,300, MRSA CC5, CC8, CC45, CC80, CC152	37.5 ± 13.2 μg/mL; 97.5 ± 27.5 μg/mL; 110.8 ± 21.1 μg/mL	Antibacterial	Božić et al. (2015)
Chalcones and derivatives (6s e12a)	Synthetic	Claisen–Schmidt	Newman (MSSA); MN8 (MRSA); NRS70 (MRSA)	3.12 μg/mL; 6.25 μg/mL: 0.8 μg/mL	Antibacterial, anti-biofilm	Zhang et al. (2018a, b)
(E)-N-(3-Aminopropyl)-2-(5-((3-methylbut-2-en-1-yl)oxy)-2-(3-(4-((3-methylbut-2-e n-1-yl)oxy)phenyl)acryloyl)phenoxy)acetamide	Synthetic	–	ATCC29213, MRSA N315, MRSA NCTC10442	1.56–3.13 μg/mL	Antibacterial	Lin et al. (2020)
Thiazolyl-pyrazoline derivatives (7 a)	Synthetic	Claisen–Schmidt	MSSA (ATCC 25,923), MRSA (ATCC 43,300), VISA	62.5 µg/mL; 125 µg/mL; 31.5 µg/mL;	Antibacterial	Cuartas et al. (2020)
Derivatives of benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide	Synthetic	–	ATCC 6538	> 1600 µg/mL	Inactive for antibacterial activity	Bassin et al. (2017)
Derivatives of 2′,6′-dihydroxy-4′-methoxy-3′,5′-dimethyl chalcone (10)	Synthetic	–	ATCC 43,300, Clinical isolate, VRS 10, NRS 17, NRS 1	> 128 µg/mL 64 µg/mL 32 µg/mL	Antibacterial	Kumar et al. (2016)
Derivatives of (E)-3-(4-bromophenyl)-1-(p-tolyl) prop-2-en-1-one (3a, 3e, 3j)	Synthetic	–	ATCC 29,737	25.4 mm 27.2 mm 26.4 mm	Antibacterial	Bhirud et al. (2020)
7,4′-dihydroxy-8,3′-diprenylflavone and erysubin F	Synthetic	Claisen–Schmidt	MRSA, ATCC 43,300	15.4 μM 20.5 μM	Antibacterial	Kwesiga et al. (2020)
(2Z)-3-(3-nitrophenyl)-1-{4-[(E)-(piperidin-1-yl)diazenyl]phenyl}prop-2-en-1-one	Synthetic	Claisen–Schmidt	ATCC 12,598	12.5 g/mL	Antibacterial	Sivasankerreddy et al. (2018)
Xanthohumol, naringenin, and chalconaringenin	Synthetic	–	PCM 2054	3.57 mm 3.77 mm 1.92 mm	Antibacterial	Stompor and Zarowska (2016)
2′-Hydroxychalcone; 2 0-Hydroxy-2-methoxychalcone; 2 0-Hydroxy-4-methoxychalcone; 2 0-Hydroxy-40 -methoxychalcone-3-yl)(3-bromophenyl)methanone	Synthetic	Claisen–Schmidt	D1	0.26 ± 0.09, 0 ± 0.03, 0.88 ± 0.10 0 ± 0.04	Antibacterial	Gładkowski et al. (2019)
4-Hydroxyphenyl 3-Hydroxyphenyl	Synthetic	Claisen–Schmidt	–	5 µg/mL 10 µg/mL	Antibacterial	Desai et al. (2017)
Aryl substituted dihydrotriazine derivatives (17h)	Synthetic	–	4220 QRSA CCARM 3505	0.5 µg/mL	Antibacterial	Zhang et al. (2018a)
Derivatives of 1,2,3-triazoles (25)	Synthetic	Claisen–Schmidt	–	MIC decrease in 55%	Antibacterial	Syed-Aly et al. (2015)
Derivatives of (2-(Pyridinyl)methylene)-1-tetralone Chalcones (5h)	Synthetic	–	MRSA	Decrease of 75%	Antibacterial	Gibson et al. (2017)
(E)-N-(4-(3-(4-Chlorophenyl)acryloyl)phenyl)-3-(piperidin-1-yl)propanamide, (E)-N-(4-(3-(4-Methoxyphenyl)acryloyl)phenyl)-3-(piperidin-1-yl)propanamide, (E)-3-(Piperidin-1-yl)-N-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenyl)propanamide	Synthetic	–	IFO 3060	2.0 mg/mL 2.4–8.6 mg/mL	Antibacterial and anti-biofilm	El-Messery et al. (2018)
(2E)-3-(4-{[1-(2-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy}-3- methoxyphenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one, (2E)-3-(4-{[1-(2,4-difluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy}-3-methoxyphenyl)-1- (2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one, (2E)-3-(4-{[1-(2-chlorophenyl)-1H-1,2,3-triazol-4-yl]methoxy}-3-methoxyphenyl)-1-(2- hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one, (2E)-3-[3,4-bis({[1-(2,4-difluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy})phenyl]-1-(2- hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one, 2-[3,4-bis({[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]methoxy})phenyl]-5,7-dimethoxy4H-chromen-4-one	Synthetic	–	ATCC 25323	6.25 µg/mL 12.5 µg/mL	Antibacterial	Kant et al. (2016)
4′-hydroxy-4-methyl chalcone	Synthetic	–	ATCC 29213	32 μg/mL	Antibacterial	Evranos-Aksöz et al. (2015)
Asymmetric heterocyclic chalcone derivatives and heterocyclic compounds (4, 6, 7, 9)	Synthetic	–	ATCC 25923	65–95% of zone of inhibition	Antibacterial	El-Hashash et al. (2015)
Derivatives of 3-hydroxy-6-(hydroxymethyl)-2-(2-phenyl-4H-chromen-4-yl)-4H-pyran-4-ones (3a, 3e, 3f e 3 l)	Synthetic	–	MLS-16 MTCC 2940	7.8–15.6 µg/mL	Antibacterial	Bingi et al. (2015)
Chalcona derivative: (4[(1E)-3-(pentyloxy)buta-1,3- dien-1-yl]benzene-1,2-diol	Synthetic	Claisen–Schmidt	ATCC 2592 (MRSA) ATCC 33591	0.12 μM	Antibacterial and antibiofilm	Emeri et al. (2019)
N-(5a-chloro, 8a-triflouromethyl)-benzyl-N, 1a-dihydro-2H-O, N-isoliquiritigeninoxazine (IMRG4)	Synthetic Derived from the natural Chalcone Isoliquiritigenin (ISL)	–	SA-29213; SA-1199;SA-1199B*; SA-K1758; MRSA-P4423; MRSA-P4627; MRSA-P4620; MRSA-B10760; MRSA-ST315; VISA-ST207; VISA-ST1745	50 (mg/L); 25(mg/L); 50(mg/L); 25 (mg/L); 50(mg/L); 25(mg/L); 25 (mg/L); 50(mg/L); 25(mg/L); 50 (mg/L); 50(mg/L)	Antibacterial *NorA efflux pump inhibitor	Gupta et al. (2019)
(2E)-1-(3′, -methoxy-4′,-hydroxyphenyl)-3-(3-nitrophenyl) prop-2-en1-one (AVMNB)	Synthetic	Claisen–Schmidt	ATCC 25923; 10	≤ 512 mg/mL	Antibacterial	Garcia et al. (2020)
(2E)-1-(3′, -methoxy-4′,-hydroxyphenyl)-3-(3-nitrophenyl) prop-2-en1-one (AVMNB)	Synthetic	Claisen–Schmidt	ATCC 25923; 10	MIC↑	Antagonistic with Cephalexin and Gentamicin antibiotics	Garcia et al. (2020)
2E-1-(2ʹ-hidroxi-3ʹ,4ʹ,6ʹ-trimetoxifenil)-3-(fenil)-prop-2-en-1-ona (HYTPHENYL)	Synthetic Derived from the natural compound: 2-hydroxy-3,4,6-trimethoxyacetophenone	Claisen–Schmidt	358	1024 µg/L MIC↓	Inactive for antibacterial activity Antibiotic modulator: Synergism with the antibiotic Amikacin	Teixeira et al. (2019)
(E)-3-(2-methylpyrimidin-5-yl)-1-ferroceynlprop-2-en-1-one (MPFP)	Synthetic	Claisen–Schmidt	–	Concentration of 25 μg: 19 mm Concentration of 50 μg: 24 mm Concentration of 75 μg: 31 mm	Antibacterial	Twinkle et al. (2020)
Cationic derivatives of Chalcones: 5a; 5s; 5b; 5c; 5d, 5g, 5l, 5p, 5q; 5r; 5z; 5ab	Synthetic	Claisen–Schmidt	M1-M9 MRSA	Ranged from 0.25 –32 µg/mL	Antibacterial and synergism with Norfloxacin and Colistin	(CHU et al., 2018)
Cationic molecule 5g	Synthetic	Claisen–Schmidt	ATCC29213	128 µg/mL	Anti-biofilm	(CHU et al., 2018)
Chalcones derivatives: (E)-2-(4-acetamidophenoxy)-N-(3-(3-(4-methoxyphenyl) acryloyl)phenyl)acetamide (5e); (E)-2-(4-acetamidophenoxy)-N-(3-(3-(4-chlorophenyl)acryloyl) phenyl)acetamide (5b)	Synthetic	–	–	Concentration of 100 μg/mL: 9; 10 mm Concentration of 200 μg/mL: 15 mm; 13 mm	Antibacterial	Babu and Selvaraju (2020)
Chalcones-Sulfonamides 5/6, 8a-f and 9a-f (N = 12 derivatives)	Synthetic	Claisen–Schmidt	Resistant clinical isolates	> 57 mcM	Inactive for antibacterial activity	Castaño et al. (2019)
Thiazole-based Chalcone (Derivative): Compound 18	Synthetic	–	IFO 3060	1 μg/mL	Antibacterial	Alrohily et al. (2019)
Ferrocenyl Chalcone Derivatives: Zn (II) (H1; H5)	Synthetic	–	ATCC 9144	1.349 × 10–8 M/mL 1.268 × 10–7 M/mL	Significant antibacterial	Liu et al. (2019)
Derivative: (E)-1-(4-brom ophenyl)-3-(4-iodophenyl)prop-2-en-1-one	Synthetic	Synthesized and characterized using XRD, FT-IR1 H and 13 C NMR	ATCC 12600	250 μg/mL	Antibacterial	Zainuri et al. (2017)
Ferrocenyl Chalcone Derivatives: 3a2,3a7 e 3b6	Synthetic	–	MRSA, ATCC 43300	Concentração de 3 g/L: 11–22 mm	Antibacterial	Liu et al. (2018)
Chalcones derivatives: 4a; 4e; 4h	Synthetic	Claisen–Schmidt	ATCC-9144	08 µg/mL 08 µg/mL 04 µg/mL	Antibacterial	Gopi et al. (2016)
(E)-1-(4-Bromophenyl)-3-(napthalen-2-yl)prop-2-en-1-one	Synthetic	Claisen–Schmidt	ATCC 12600	500 µg/mL	Antibacterial	Thanigaimani et al. (2015)
Derivatives if indolyl-4H-chromene-phenylprop-2-en-1-one (5g; 5h)	Synthetic	Claisen–Schmidt	ATCC 700699	9.3 µg/mL	Antibacterial	Subbareddy et al. (2018)
Chalcone derivative: 1-hydroxynaphth-2-yl pyrazoline (6b)	Synthetic	Claisen–Schmidt	–	3.9 µg/mL	Antibacterial	El-Desoky et al, (2018)
Chalcone derivative: Pyrazoles (5j; 5h)	Synthetic	Claisen–Schmidt	MTCC 3160	6.5 µg/mL	Antibacterial	Mishra et al. (2017)
Derivative of Chalcone (4-bromophenyl)-1-(4-chlorophenyl)prop-2-en-1-one (I): 4-[(E){[4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl]imino}methyl]benzene-1,3-diol (IJ)	Synthetic	Claisen–Schmidt	NCIM 2079	500 µg/mL	Antibacterial	Prasad et al. (2019)
[(Chloroquinolin-4-yl)amino]chalcones 8a–f	Synthetic	Claisen–Schmidt	ATCC 25923 (MSSA) ATCC 43300 (MRSA)	> 1000 µg/mL	Inactive for antibacterial activity	Ramírez-Prada et al. (2017)
Bichalcones 8 (a–h)	Synthetic	Claisen–Schmidt	–	16–32 µg/mL	Low antibacterial activity	Yusuf and Solanki (2017)

a) The spaces filled with (–) mean that the information was absent from the article or was not clear